Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 954 participants.

Also called NCT03332771

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 954 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03332771
  • EudraCT 2016-001801-17
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Bulgaria, Hungary, Slovakia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03332771. Randomized; quadruple masking; primary purpose treatment. Start 2017-12-01 (actual); primary completion 2019-08-06 (actual). Results posted on 2021-05-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy
Acronym
SOTA-GLIM
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Sotagliflozin (SAR439954)
Intervention (Drug)
Glimepiride
Intervention (Drug)
Metformin
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Lead sponsor
Lexicon Pharmaceuticals (class: industry)
Collaborator
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct03332771
Content hash
2563c9fb63eac4ba586521af143566f8fca057dee07b58914769f35c55636ceb